UMC Utrecht
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, UMC Utrecht sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
UMC Utrecht: 4 sponsored US clinical trials, 2 recruiting.
UMC Utrecht sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Aldosteronism Due to Conn Adenoma, with 1 trials.
Upper-quartile sponsor footprint
UMC Utrecht sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT04075305
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
NCT02735707
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)
NCT04117113
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
NCT04761354
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where UMC Utrecht enrollment is open (later-stage tilt)
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Primary Aldosteronism Due to Conn Adenoma (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
UMC Utrecht: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
UMC Utrecht sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this UMC Utrecht page
4 registered trials is a research-attention snapshot, not an endorsement of UMC Utrecht or any single study.
- 2 of UMC Utrecht's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Aldosteronism Due to Conn Adenoma is the condition UMC Utrecht studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Aldosteronism Due to Conn Adenoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. UMC Utrecht pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.